Administered for1 hour every 3 weeks
SYLVANT® (siltuximab) dosing and administration1
SYLVANT is administered by intravenous infusion once every 3 weeks until treatment failure. Preadministration tests are conducted before the treatment. See below or download the detailed Dosing and Administration Guide for specific information related to tests, infusion preparation, and more.DOWNLOAD
Laboratory tests ensure effective use of SYLVANT1
Hematology laboratory tests should be performed prior to each dose of SYLVANT therapy for the first 12 months and every 3 dosing cycles thereafter. If the treatment criteria in the table below are not met, consider delaying treatment until values improve. Do not reduce the dose.
It is not safe to administer SYLVANT to patients with severe infections.
aSYLVANT may increase hemoglobin levels in patients with multicentric Castleman disease.
Preparing for an infusion1
Calculate the dose (mg) and total volume (mL) of reconstituted SYLVANT solution required and the number of vials needed.
Allow the vial(s) of SYLVANT to come to room temperature over approximately 30 minutes. SYLVANT should remain at room temperature for the duration of the preparation.
Aseptically reconstitute each SYLVANT vial as instructed in the table above.
Once reconstituted, and prior to further dilution, inspect the vials for particulates and discoloration. Do not use if particles or solution discoloration are present or if visibly opaque. The reconstituted product should be kept for no more than 2 hours prior to addition into the infusion bag.
Dilute the reconstituted SYLVANT solution dose in the infusion bag. Administer SYLVANT over 1 hour by infusion.
DO NOT SHAKE or SWIRL VIGOROUSLY
GENTLY swirl the reconstituted vials to aid the dissolution of the lyophilized powder
Do not remove the contents until all of the solids have been completely dissolved
The lyophilized powder should dissolve in less than 60 minutes
Do not mix with saline
Your patients may be eligible for home infusions
THospitals, clinics, and infusion centers offer the expertise and care that your patients deserve, but some patients may have to travel for hours to get to one. Home infusions can help prevent disruptions in a patient’s treatment plan.
Patients who choose to receive a home infusion must receive their first SYLVANT infusion at a clinic or hospital before transitioning to home infusion.
To start the enrollment process, or for additional information, please contact your EUSA Pharma representative or a Coram® CVS Specialty® Infusion Services representative.
Disclaimer: Insurance coverage of home infusion treatments varies by patients' provider and plan. SYLVANT® (siltuximab) treatment must be initiated in an office or clinic setting before transitioning to home infusion.
Reference: 1.SYLVANT [package insert]. Hertfordshire, UK: EUSA Pharma (UK) Ltd; 2019.